Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 921 of 1,261
  1. US 8187817

    Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies

    XBIOTECH INC. · Granted May 29, 2012 · Expires May 24, 2032

    granted
  2. US 8187874

    Drug discovery method

    Vertex Pharmaceuticals Incorporated · Granted May 29, 2012 · Expires May 24, 2032

    granted
  3. US 8188067

    Formulations of 6-mercaptopurine

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 29, 2012 · Expires May 24, 2032

    granted
  4. US 8188049

    Peptides having activities of epidermal growth factor and its uses

    CAREGEN CO., LTD. · Granted May 29, 2012 · Expires May 24, 2032

    granted
  5. US 8188055

    Inactivators of O6-alkylguanine-DNA alkyltransferase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 29, 2012 · Expires May 24, 2032

    granted
  6. US 8188061

    RNAi modulation of APOB and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 29, 2012 · Expires May 24, 2032

    granted
  7. US 8188072

    Benzodiazepinone compounds useful in the treatment of skin conditions

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted May 29, 2012 · Expires May 24, 2032

    granted
  8. US 8188149

    Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 29, 2012 · Expires May 24, 2032

    granted
  9. US 8188214

    Brachyury polypeptides and methods for use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted May 29, 2012 · Expires May 24, 2032

    granted
  10. US 8188095

    Gyrase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted May 29, 2012 · Expires May 24, 2032

    granted
  11. US 8188132

    Linked dibenzimidazole derivatives

    Enanta Pharmaceuticals, Inc. · Granted May 29, 2012 · Expires May 24, 2032

    granted
  12. US 8188219

    Bone morphogenic protein binding peptide

    The Regents of the University of California · Granted May 29, 2012 · Expires May 24, 2032

    granted
  13. US 8188221

    Peptide homing to brain tumors

    The Regents of the University of California, UCSF · Granted May 29, 2012 · Expires May 24, 2032

    granted
  14. US 8188276

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted May 29, 2012 · Expires May 24, 2032

    granted
  15. US 8183207

    Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules

    Five Prime Therapeutics, Inc. · Granted May 22, 2012 · Expires May 17, 2032

    granted
  16. US 8183014

    High affinity antibodies to human IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted May 22, 2012 · Expires May 17, 2032

    granted
  17. US 8183338

    Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof

    Nektar Therapeutics · Granted May 22, 2012 · Expires May 17, 2032

    granted
  18. US 8183204

    Methods and compositions for increasing skin remodeling

    Summit Associates International Inc. · Granted May 22, 2012 · Expires May 17, 2032

    granted
  19. US 8183282

    Therapeutic uses of urolithins

    The Regents of the University of California · Granted May 22, 2012 · Expires May 17, 2032

    granted
  20. US 8182807

    Method for inhibiting reperfusion injury in the brain

    Board of Regents of the University of Nebraska by and behalf of the University of Nebraska Medical Center · Granted May 22, 2012 · Expires May 17, 2032

    granted
  21. US 8183274

    Treatment of hyperproliferative disorders with diarylhydantoin compounds

    The Regents of the University of California · Granted May 22, 2012 · Expires May 17, 2032

    granted
  22. US 8183285

    Therapeutic agent for irritable bowel syndrome and methods thereof

    Takeda Pharmaceutical Company Limited · Granted May 22, 2012 · Expires May 17, 2032

    granted
  23. US 8183361

    Oligonucleotide-containing pharmacological compositions and their use

    Lakewood Amedex, Inc. · Granted May 22, 2012 · Expires May 17, 2032

    granted
  24. US 8183344

    Inactivation resistant factor VIII

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted May 22, 2012 · Expires May 17, 2032

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.